Exact Sciences reported a record third quarter in 2025, with revenue increasing 20% year-over-year to $851 million, driven by robust performance in its Cologuard product line and the successful launch of Cancerguard.

• Total revenue reached $851 million, surpassing guidance by $43 million, with screening revenue increasing 22% to $666 million.
• Adjusted EBITDA rose 37% to $135 million, with margins expanding to 16%.
• Free cash flow doubled to $190 million, highlighting improved collections and working capital management.
• Full-year revenue guidance raised to $3.22–$3.235 billion, reflecting strong momentum in the core business.
• Cologuard Plus demonstrated significant improvements in sensitivity and specificity, enhancing its market positioning amid expanded payer coverage.